Tan et al. (2023) conducted an observational cohort study comparing once-weekly GLP-1 RAs to DPP-4 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD) [21]. Here, GLP1R is linked to atherosclerosis.